Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil I Daud

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
American Journal of Clinical Dermatology|February 8, 2024
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous MelanomaAlexandra Haugh, Adil I Daud
Human Vaccines & Immunotherapeutics|May 13, 2022
Intratumoral therapies and in-situ vaccination for melanomaLaura A Huppert, Adil I Daud
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Immunotherapy for melanomaLauren M Cuevas, Adil I Daud
Hematology/Oncology Clinics of North America|June 2, 2014
Combinatorial approach to treatment of melanomaMichelle T Ashworth, Adil I Daud
The Journal of Clinical Investigation|October 15, 2024
Distinguishing between help and harm: Helper T cell subsets and immune-related adverse eventsAlexandra M Haugh, Adil I Daud
Journal of Hematology & Oncology|November 1, 2015
Nivolumab plus ipilimumab in the treatment of advanced melanomaKaty K Tsai, Adil I Daud
Cancer Control : Journal of the Moffitt Cancer Center|July 4, 2008
Melanoma: promising new discoveries and treatment modalities for difficult clinical scenariosJonathan S Zager, Adil I Daud
Expert Opinion on Investigational Drugs|October 12, 2011
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanomaPamela N Munster, Adil I Daud
Drugs|March 25, 2015
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to DateKaty K Tsai, Adil I Daud
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced MelanomaLaura A Huppert, Adil I Daud
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
American Journal of Clinical Dermatology|February 8, 2024
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous MelanomaAlexandra Haugh, Adil I Daud
Human Vaccines & Immunotherapeutics|May 13, 2022
Intratumoral therapies and in-situ vaccination for melanomaLaura A Huppert, Adil I Daud
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Immunotherapy for melanomaLauren M Cuevas, Adil I Daud
Hematology/Oncology Clinics of North America|June 2, 2014
Combinatorial approach to treatment of melanomaMichelle T Ashworth, Adil I Daud
The Journal of Clinical Investigation|October 15, 2024
Distinguishing between help and harm: Helper T cell subsets and immune-related adverse eventsAlexandra M Haugh, Adil I Daud
Journal of Hematology & Oncology|November 1, 2015
Nivolumab plus ipilimumab in the treatment of advanced melanomaKaty K Tsai, Adil I Daud
Cancer Control : Journal of the Moffitt Cancer Center|July 4, 2008
Melanoma: promising new discoveries and treatment modalities for difficult clinical scenariosJonathan S Zager, Adil I Daud
Expert Opinion on Investigational Drugs|October 12, 2011
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanomaPamela N Munster, Adil I Daud
Drugs|March 25, 2015
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to DateKaty K Tsai, Adil I Daud
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced MelanomaLaura A Huppert, Adil I Daud
Pageof 9